NDAURETHRALSOLUTION
Approved
Aug 1955
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 8h ago · AI intelligence enriched 2w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
CYSTOGRAFIN (diatrizoate meglumine) is a urethral contrast solution used for cystography and urethral imaging procedures. It is a small-molecule iodinated organic compound that provides radiographic visualization of the urinary bladder and urethra. This legacy diagnostic agent has been in clinical use since 1955.
LOE Approaching
Mature diagnostic product approaching loss of exclusivity with limited growth prospects; commercial team likely minimal or consolidating resources.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
CYSTOGRAFIN offers limited career growth opportunities as a legacy diagnostic product in LOE phase with zero linked job openings. Roles on this product are primarily maintenance-focused, centered on maximizing remaining exclusivity and managing transition to generic competition.
Product ManagerMarketing Manager
Worked on CYSTOGRAFIN at Bracco? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.